Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ITRM Stock Summary
Top 10 Correlated ETFs
ITRM
In the News
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Thursday, March 28, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
Iterum Therapeutics to Present Data at IDWeek 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America's IDWeek 2023 conference taking place in Boston, MA from October 11-15, 2023.
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
Iterum Therapeutics to Present Data at ASM Microbe 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief Executive Officer Judy Matthews – Chief Financial Officer Conference Call Participants Ed Acre – H.C. Wainwright Operator Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call.
Iterum Therapeutics to Present Data at IDWeek 2022
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America's IDWeek 2022.
ITRM Financial details
ITRM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.49 | 0.04 | 0 | 0 | 0 | |
Net income per share | -132.34 | -106.55 | -32.49 | -8.41 | -3.63 | |
Operating cash flow per share | -130.33 | -81.5 | -34.07 | -1.45 | -1.51 | |
Free cash flow per share | -130.49 | -81.53 | -34.07 | -1.46 | -1.51 | |
Cash per share | 145.21 | 4.96 | 10.54 | 7.47 | 4.97 | |
Book value per share | 123 | -27.11 | -31.59 | 4.61 | 2.29 | |
Tangible book value per share | 123 | -27.11 | -31.59 | 4.3 | 2.15 | |
Share holders equity per share | 123 | -27.11 | -31.59 | 4.61 | 2.29 | |
Interest debt per share | 24.94 | 14.76 | 35.88 | 2.95 | 2.55 | |
Market cap | 43.76M | 65.33M | 23.75M | 64.04M | 10.28M | |
Enterprise value | 12.29M | 68.16M | 45.1M | 61.49M | 17.65M | |
P/E ratio | -0.57 | -0.63 | -0.46 | -0.7 | -0.23 | |
Price to sales ratio | 50.35 | 1.77K | 0 | 0 | 0 | |
POCF ratio | -0.58 | -0.83 | -0.44 | -4.04 | -0.56 | |
PFCF ratio | -0.58 | -0.83 | -0.44 | -4.03 | -0.55 | |
P/B Ratio | 0.61 | -2.49 | -0.47 | 1.27 | 0.37 | |
PTB ratio | 0.61 | -2.49 | -0.47 | 1.27 | 0.37 | |
EV to sales | 14.14 | 1.84K | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.16 | -0.67 | -1.3 | -2.53 | -0.49 | |
EV to operating cash flow | -0.16 | -0.86 | -0.83 | -3.88 | -0.96 | |
EV to free cash flow | -0.16 | -0.86 | -0.83 | -3.87 | -0.95 | |
Earnings yield | -1.76 | -1.58 | -2.19 | -1.43 | -4.32 | |
Free cash flow yield | -1.74 | -1.21 | -2.3 | -0.25 | -1.8 | |
Debt to equity | 0.2 | -0.51 | -0.84 | 0.53 | 1.03 | |
Debt to assets | 0.14 | 0.52 | 1.29 | 0.29 | 0.43 | |
Net debt to EBITDA | 0.41 | -0.03 | -0.61 | 0.1 | -0.21 | |
Current ratio | 6.93 | 0.13 | 0.5 | 13.43 | 310.4 | |
Interest coverage | -179.72 | -118.49 | -2.13 | -4.42 | -12.87 | |
Income quality | 0.98 | 0.76 | 1.05 | 0.17 | 0.42 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 10.1 | 304.97 | 0 | 0 | 0 | |
Research and developement to revenue | 79 | 2.45K | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0.04 | 0.03 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.1 | -0.65 | 0 | 0 | 0 | |
Capex to depreciation | -0.66 | -0.16 | -0.07 | -0.03 | -0.03 | |
Stock based compensation to revenue | 1.48 | 58.73 | 0 | 0 | 0 | |
Graham number | 605.19 | 254.94 | 151.96 | 29.54 | 13.67 | |
ROIC | -0.9 | 16.89 | 10.69 | -0.31 | -0.53 | |
Return on tangible assets | -0.79 | -4 | -1.59 | -1.04 | -0.68 | |
Graham Net | 94.3 | -52.04 | -42.3 | 3.62 | 1.75 | |
Working capital | 72.45M | -32.19M | -14.36M | 75.29M | 60.64M | |
Tangible asset value | 71.62M | -26.24M | -50.56M | 46.8M | 26.28M | |
Net current asset value | 58.42M | -47.19M | -68.84M | 40.07M | 22M | |
Invested capital | 0.2 | -0.51 | -0.84 | 0.53 | 1.03 | |
Average receivables | 615K | 916K | 988K | 1.04M | 859K | |
Average payables | 3.6M | 9.76M | 8.15M | 847K | 1.83M | |
Average inventory | -3.93M | -7.95M | -5.88M | -3.43M | -2.49M | |
Days sales outstanding | 302.84 | 10.96K | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 1.85K | 152.31 | 562.51 | |
Days of inventory on hand | 0 | 0 | -8.48K | -542.47 | -375.34 | |
Receivables turnover | 1.21 | 0.03 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0.2 | 2.4 | 0.65 | |
Inventory turnover | 0 | 0 | -0.04 | -0.67 | -0.97 | |
ROE | -1.08 | 3.93 | 1.03 | -1.82 | -1.59 | |
Capex per share | -0.15 | -0.02 | -0.01 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.38 | -0.41 | -0.78 | -0.95 | -0.3 | |
Operating cash flow per share | -0.37 | -0.35 | -0.76 | -0.59 | -0.71 | |
Free cash flow per share | -0.37 | -0.35 | -0.76 | -0.59 | -0.71 | |
Cash per share | 5.26 | 4.95 | 4.09 | 3.46 | 2.75 | |
Book value per share | 2.66 | 2.28 | 1.49 | 0.55 | 0.26 | |
Tangible book value per share | 2.49 | 2.14 | 1.39 | 0.48 | 0.26 | |
Share holders equity per share | 2.66 | 2.28 | 1.49 | 0.55 | 0.26 | |
Interest debt per share | 2.55 | 2.34 | 2.43 | 2.52 | 1.55 | |
Market cap | 19.82M | 10.33M | 12.68M | 13.85M | 10.44M | |
Enterprise value | 29.54M | 17.7M | 25.99M | 32.03M | 25.22M | |
P/E ratio | -0.17 | -0.51 | -0.32 | -0.28 | -0.67 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.37 | -2.42 | -1.32 | -1.81 | -1.13 | |
PFCF ratio | -4.36 | -2.4 | -1.32 | -1.81 | -1.13 | |
P/B Ratio | 0.61 | 0.37 | 0.67 | 1.94 | 3.04 | |
PTB ratio | 0.61 | 0.37 | 0.67 | 1.94 | 3.04 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -1.24 | -1.63 | -3.23 | -3.1 | -1.56 | |
EV to operating cash flow | -6.51 | -4.15 | -2.71 | -4.2 | -2.72 | |
EV to free cash flow | -6.5 | -4.11 | -2.71 | -4.19 | -2.72 | |
Earnings yield | -1.47 | -0.49 | -0.78 | -0.88 | -0.37 | |
Free cash flow yield | -0.23 | -0.42 | -0.76 | -0.55 | -0.89 | |
Debt to equity | 0.94 | 1.03 | 1.61 | 4.53 | 5.8 | |
Debt to assets | 0.43 | 0.43 | 0.52 | 0.63 | 0.5 | |
Net debt to EBITDA | -0.41 | -0.68 | -1.65 | -1.76 | -0.91 | |
Current ratio | 8.88 | 310.4 | 6.96 | 4.4 | 2.35 | |
Interest coverage | -11.06 | 99.08 | -21.38 | -33.4 | -55.62 | |
Income quality | 0.16 | 0.84 | 0.97 | 0.62 | 2.39 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.02 | -0.1 | 0 | -0.04 | 0.01 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 11.94 | 4.61 | 5.12 | 3.42 | 1.33 | |
ROIC | -0.11 | -0.14 | -0.17 | -0.27 | -0.74 | |
Return on tangible assets | -0.42 | -0.08 | -0.17 | -0.24 | -0.1 | |
Graham Net | 2.12 | 1.75 | 1 | 0.07 | -0.02 | |
Working capital | 59.14M | 60.64M | 46.45M | 36.82M | 22.13M | |
Tangible asset value | 30.4M | 26.28M | 17.67M | 6.27M | 3M | |
Net current asset value | 27.65M | 22M | 15.08M | 3.76M | 2.23M | |
Invested capital | 0.94 | 1.03 | 1.61 | 4.53 | 5.8 | |
Average receivables | 621.5K | 654K | 410.5K | 217.5K | 148.5K | |
Average payables | 1.01M | 2M | 2.5M | 2.98M | 4.61M | |
Average inventory | 0 | -925.5K | -1.08M | -217.5K | -63.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 246.9 | 568.7 | 461.35 | 763.36 | 1.14K | |
Days of inventory on hand | 0 | -379.48 | -63.58 | -26.1 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.36 | 0.16 | 0.2 | 0.12 | 0.08 | |
Inventory turnover | 0 | -0.24 | -1.42 | -3.45 | 0 | |
ROE | -0.89 | -0.18 | -0.52 | -1.72 | -1.13 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ITRM Frequently Asked Questions
What is Iterum Therapeutics plc stock symbol ?
Iterum Therapeutics plc is a IE stock and trading under the symbol ITRM
What is Iterum Therapeutics plc stock quote today ?
Iterum Therapeutics plc stock price is $1.54 today.
Is Iterum Therapeutics plc stock public?
Yes, Iterum Therapeutics plc is a publicly traded company.